GPRC5D targeted CAR T cell therapy - Yake Biotechnology
Alternative Names: DeepTag-GPRC5D Targeted CAR T-cell therapy; GPRC5D Targeted CAR T-cell therapyLatest Information Update: 08 Dec 2023
At a glance
- Originator Yake Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Multiple myeloma
Most Recent Events
- 20 Oct 2023 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in China (IV) (NCT06084962)